What is HIPRA?
'''Hipra''' Laboratories, S.A. is a Spanish pharmaceutical multinational founded in 1954. It began in the field of veterinary medicine but is also developing a vaccine against [[COVID-19]].<ref>{{Cite web|last=Teixidor|first=Laura|date=2020-12-19|title=Hipra investiga una vacuna més «potent i eficaç» que les convencionals|url=https://www.diaridegirona.cat/comarques/2020/12/19/hipra-investiga-vacuna-mes-potent-48644972.html|access-date=2022-06-09|website=Diari de Girona|language=ca}}</ref> == History == The founder of the company is the Catalan pharmacist, veterinarian and [[chemist]] Joan Nogareda i Gifre, a native of [[Olot]]. In 1971, he acquired a Madrid-based companyand moved it to the province of [[Girona]] in 1954. Since 1973, its headquarters have been in Amer. His brother Ernest and Pere Casadevall are involved in the new company.<ref>{{Cite web|date=2020-11-17|title=Amer, el pueblo de Puigdemont, tiene nuevo atractivo: la vacuna anti Covid que fabrica Hipra|url=https://www.elespanol.com/reportajes/20201117/amer-pueblo-puigdemont-atractivo-covid-fabrica-hipra/536447763_0.html|access-date=2022-06-09|website=El Español|language=es}}</ref><ref>{{Cite web|last=AGENCIAS|first=RTVE es /|date=2021-11-15|title=Aprobada la fase 2 de ensayos en humanos para la vacuna de Hipra|url=https://www.rtve.es/noticias/20211115/fase-2-ensayos-humanos-vacuna-hipra/2224743.shtml|access-date=2022-06-09|website=RTVE.es|language=es}}</ref> == Human health == Since April 2020, Hipra has been developing a vaccine against SARS-CoV-2 with funding from the CDTI.2 Later, in November 2021, the vaccine went to phase 2 of human trials3, to finally start phase 3 in early 2022 with 3,000 volunteers in 20 hospitals, mainly from [[Spain]] but also from [[Italy]] and [[Portugal]]. The company expects to make 400 million doses in 2022, having already agreed a supply of 50 million doses with [[Vietnam]].<ref>{{Cite web|last=Figuls|first=Josep Catà|date=2021-09-13|title=Hipra acuerda con Vietnam el primer suministro de su vacuna contra la covi